December 1, 2013

Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer

PUBLICATION: 
European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773–3779

AUTHORS: 
V.P. Retèl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten

SUMMARY: 
The total health care costs per patient were €26,786 for the 70-gene and €29,187 for AO. The quality adjusted life years yielded 12.49 and 11.88, respectively. The subgroups retrieved slightly higher life gains and higher costs, but all resulted finally in a favourable position for the 70-gene signature (based on RASTER).

Read more: Retèl et al_2013_European Journal of Cancer_Prospective Cost-Effectiveness Analysis…